Comparative Pharmacology
Head-to-head clinical analysis: NEXPLANON versus NEXTSTELLIS.
Peer-Reviewed Evidence
Head-to-head clinical analysis: NEXPLANON versus NEXTSTELLIS.
NEXPLANON vs NEXTSTELLIS
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Progestin-only contraceptive that suppresses ovulation primarily by inhibiting the mid-cycle LH surge. It also thickens cervical mucus, impeding sperm penetration, and alters endometrial lining.
Combination oral contraceptive: estrogen (estetrol) and progestin (drospirenone) suppress gonadotropin release, inhibiting ovulation; increase cervical mucus viscosity, impeding sperm penetration; alter endometrial lining, reducing implantation likelihood.
68 mg subdermal implant inserted in the inner upper arm; provides contraception for up to 3 years.
One tablet orally once daily, each tablet containing drospirenone 3 mg and estetrol 14.2 mg, taken continuously without a break.
None Documented
None Documented
Terminal elimination half-life approximately 25 hours (range 20-30 hours) after removal; steady-state achieved within 3-4 days; clinical effect persists for 3-4 weeks post-removal due to residual subcutaneous depot.
Drospirenone: 30 hours; ethinyl estradiol: 12 hours. The long half-life allows once-daily dosing and stable serum concentrations.
Renal (40-50% as metabolites), fecal (30-40% as metabolites), with <1% unchanged in urine; enterohepatic circulation contributes to prolonged elimination.
Urine (60%) and feces (35%); drospirenone and metabolites, with enterohepatic recirculation.
Category C
Category C
Contraceptive
Contraceptive